ClinicalTrials.Veeva

Menu

The Effect of Tyrosine Kinase Receptor Axl on Dialysis Prognosis in Chronic Hemodialysis Patients

A

Ai Peng

Status

Unknown

Conditions

Hemodialysis Complication

Study type

Observational

Funder types

Other

Identifiers

NCT04600219
AHD2020

Details and patient eligibility

About

The purpose of this study is to evaluate whether tyrosine kinase receptor Axl affects the dialysis prognosis in chronic hemodialysis patients

Full description

It is reported that hemodialysis (HD) patients often develop chronic systemic inflammatoion, and increased inflammatory activity is associated with vascular access failure, cardiovascular disease and death in HD patients. The interaction of Axl and its ligand Gas6 plays an important role in modulating immune response, inhabiting toll-like receptor (TLR) signaling and suppressing inflammatory cytokines production. Thus, we want to investigate the relationship between tyrosine kinase receptor Axl and the dialysis prognosis in HD patients in three-years follow-up.

Enrollment

250 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • hemodialysis for more than 6 months

Exclusion criteria

  • patients who received warfarin therapy;
  • patients with chronic infectious disease or acute infection;
  • patients with hemodialysis inadequacy;
  • the age of patients is older than 65 years or younger than 18 years.
  • patients who can not sign an informed consent or disagree to follow up

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems